25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Enanta Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Enanta Pharmaceuticals Inc together

I guess you are interested in Enanta Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Enanta Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Enanta Pharmaceuticals Inc

I send you an email if I find something interesting about Enanta Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Enanta Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Enanta Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€4.83
Expected worth in 1 year
€1.30
How sure are you?
7.1%

+ What do you gain per year?

Total Gains per Share
€-3.53
Return On Investment
-58.8%

For what price can you sell your share?

Current Price per Share
€6.00
Expected price per share
€4.58 - €8.95
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Enanta Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
€6.00
Intrinsic Value Per Share
€-56.69 - €-66.33
Total Value Per Share
€-51.86 - €-61.50

2.2. Growth of Enanta Pharmaceuticals Inc (5 min.)




Is Enanta Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$111.8m$228.9m-$90m-64.8%

How much money is Enanta Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$26.2m-$34.5m$8.3m31.7%
Net Profit Margin-159.4%-188.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Enanta Pharmaceuticals Inc (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Enanta Pharmaceuticals Inc?

Welcome investor! Enanta Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Enanta Pharmaceuticals Inc.

First you should know what it really means to hold a share of Enanta Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Enanta Pharmaceuticals Inc is €6. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Enanta Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Enanta Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €4.83. Based on the TTM, the Book Value Change Per Share is €-0.88 per quarter. Based on the YOY, the Book Value Change Per Share is €-1.23 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Enanta Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-1.04-17.4%-1.24-20.6%-1.64-27.3%-1.43-23.8%-1.43-23.8%
Usd Book Value Change Per Share-0.84-13.9%-0.96-16.0%-1.33-22.2%0.376.2%0.376.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.84-13.9%-0.96-16.0%-1.33-22.2%0.376.2%0.376.2%
Usd Price Per Share6.13-11.29-20.54-33.69-33.69-
Price to Earnings Ratio-1.47--2.26--3.03--5.87--5.87-
Price-to-Total Gains Ratio-7.33--11.65--14.56--27.16--27.16-
Price to Book Ratio1.17-1.67-1.79-2.44-2.44-
Price-to-Total Gains Ratio-7.33--11.65--14.56--27.16--27.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.513
Number of shares153
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.960.37
Usd Total Gains Per Share-0.960.37
Gains per Quarter (153 shares)-146.4357.28
Gains per Year (153 shares)-585.74229.12
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-586-5960229219
20-1171-11820458448
30-1757-17680687677
40-2343-23540916906
50-2929-2940011461135
60-3514-3526013751364
70-4100-4112016041593
80-4686-4698018331822
90-5272-5284020622051
100-5857-5870022912280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.014.00.00.0%0.014.00.00.0%0.014.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%1.013.00.07.1%1.013.00.07.1%1.013.00.07.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.014.00.0%0.00.014.00.0%0.00.014.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%1.013.00.07.1%1.013.00.07.1%1.013.00.07.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Enanta Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.770-0.882+14%-1.229+59%0.345-323%0.345-323%
Book Value Per Share--4.8286.032-20%10.007-52%11.297-57%11.297-57%
Current Ratio--5.4675.507-1%6.998-22%8.212-33%8.212-33%
Debt To Asset Ratio--0.6790.641+6%0.444+53%0.363+87%0.363+87%
Debt To Equity Ratio--2.1181.802+18%0.915+131%0.837+153%0.837+153%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value---97632661.200-5635981.400-94%215196465.100-145%507778024.514-119%507778024.514-119%
Eps---0.963-1.139+18%-1.510+57%-1.316+37%-1.316+37%
Ev To Ebitda Ratio--infnannan%infnan%nannan%nannan%
Ev To Sales Ratio---1.562-0.118-92%3.247-148%6.447-124%6.447-124%
Free Cash Flow Per Share---1.103-1.047-5%-1.084-2%-1.076-2%-1.076-2%
Free Cash Flow To Equity Per Share---1.318-1.321+0%1.000-232%-0.491-63%-0.491-63%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---66.331--------
Intrinsic Value_10Y_min---56.692--------
Intrinsic Value_1Y_max---4.816--------
Intrinsic Value_1Y_min---4.729--------
Intrinsic Value_3Y_max---15.865--------
Intrinsic Value_3Y_min---15.118--------
Intrinsic Value_5Y_max---28.597--------
Intrinsic Value_5Y_min---26.423--------
Market Cap--120531450.000220521612.500-45%398647687.600-70%644007646.714-81%644007646.714-81%
Net Profit Margin---1.314-1.594+21%-1.881+43%-1.570+19%-1.570+19%
Operating Margin----0%-0%-0%-0%
Operating Ratio--2.3882.675-11%2.934-19%2.646-10%2.646-10%
Pb Ratio1.243+6%1.1701.673-30%1.791-35%2.440-52%2.440-52%
Pe Ratio-1.558-6%-1.467-2.256+54%-3.028+106%-5.870+300%-5.870+300%
Price Per Share6.000+6%5.65010.400-46%18.925-70%31.036-82%31.036-82%
Price To Free Cash Flow Ratio-1.360-6%-1.280-2.497+95%-5.234+309%-8.269+546%-8.269+546%
Price To Total Gains Ratio-7.787-6%-7.333-11.646+59%-14.561+99%-27.155+270%-27.155+270%
Quick Ratio--2.8553.648-22%4.731-40%5.666-50%5.666-50%
Return On Assets---0.064-0.068+7%-0.083+30%-0.075+17%-0.075+17%
Return On Equity---0.199-0.191-4%-0.152-24%-0.134-33%-0.134-33%
Total Gains Per Share---0.770-0.882+14%-1.229+59%0.345-323%0.345-323%
Usd Book Value--111811818.082138909554.588-20%228944687.148-51%255280595.006-56%255280595.006-56%
Usd Book Value Change Per Share---0.836-0.957+14%-1.334+59%0.374-323%0.374-323%
Usd Book Value Per Share--5.2416.548-20%10.863-52%12.263-57%12.263-57%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value---105980253.733-6117857.810-94%233595762.866-145%551193045.610-119%551193045.610-119%
Usd Eps---1.045-1.236+18%-1.639+57%-1.429+37%-1.429+37%
Usd Free Cash Flow---25545044.580-24119847.884-6%-24796572.574-3%-24458442.363-4%-24458442.363-4%
Usd Free Cash Flow Per Share---1.197-1.136-5%-1.176-2%-1.168-2%-1.168-2%
Usd Free Cash Flow To Equity Per Share---1.431-1.434+0%1.086-232%-0.533-63%-0.533-63%
Usd Market Cap--130836888.975239376210.369-45%432732064.890-70%699070300.508-81%699070300.508-81%
Usd Price Per Share6.513+6%6.13311.289-46%20.543-70%33.689-82%33.689-82%
Usd Profit---22289166.354-26231018.923+18%-34557957.484+55%-29892096.280+34%-29892096.280+34%
Usd Revenue--16958365.73316647127.374+2%18404811.634-8%19537340.705-13%19537340.705-13%
Usd Total Gains Per Share---0.836-0.957+14%-1.334+59%0.374-323%0.374-323%
 EOD+3 -3MRQTTM+16 -19YOY+13 -225Y+9 -2610Y+9 -26

3.3 Fundamental Score

Let's check the fundamental score of Enanta Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.558
Price to Book Ratio (EOD)Between0-11.243
Net Profit Margin (MRQ)Greater than0-1.314
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.855
Current Ratio (MRQ)Greater than15.467
Debt to Asset Ratio (MRQ)Less than10.679
Debt to Equity Ratio (MRQ)Less than12.118
Return on Equity (MRQ)Greater than0.15-0.199
Return on Assets (MRQ)Greater than0.05-0.064
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Enanta Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose6.350
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Enanta Pharmaceuticals Inc

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Enanta Pharmaceuticals Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Enanta Pharmaceuticals Inc to the  industry mean.
  • A Net Profit Margin of -131.4% means that €-1.31 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Enanta Pharmaceuticals Inc:

  • The MRQ is -131.4%. The company is making a huge loss. -2
  • The TTM is -159.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-131.4%TTM-159.4%+27.9%
TTM-159.4%YOY-188.1%+28.7%
TTM-159.4%5Y-157.0%-2.4%
5Y-157.0%10Y-157.0%0.0%
4.3.1.2. Return on Assets

Shows how efficient Enanta Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Enanta Pharmaceuticals Inc to the  industry mean.
  • -6.4% Return on Assets means that Enanta Pharmaceuticals Inc generated €-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Enanta Pharmaceuticals Inc:

  • The MRQ is -6.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.4%TTM-6.8%+0.4%
TTM-6.8%YOY-8.3%+1.5%
TTM-6.8%5Y-7.5%+0.7%
5Y-7.5%10Y-7.5%0.0%
4.3.1.3. Return on Equity

Shows how efficient Enanta Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Enanta Pharmaceuticals Inc to the  industry mean.
  • -19.9% Return on Equity means Enanta Pharmaceuticals Inc generated €-0.20 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Enanta Pharmaceuticals Inc:

  • The MRQ is -19.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -19.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.9%TTM-19.1%-0.9%
TTM-19.1%YOY-15.2%-3.9%
TTM-19.1%5Y-13.4%-5.7%
5Y-13.4%10Y-13.4%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Enanta Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Enanta Pharmaceuticals Inc is operating .

  • Measures how much profit Enanta Pharmaceuticals Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Enanta Pharmaceuticals Inc to the  industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
4.3.2.2. Operating Ratio

Measures how efficient Enanta Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to  industry mean).
  • An Operation Ratio of 2.39 means that the operating costs are €2.39 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 2.388. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.675. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.388TTM2.675-0.287
TTM2.675YOY2.934-0.259
TTM2.6755Y2.646+0.028
5Y2.64610Y2.6460.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Enanta Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Enanta Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to  industry mean).
  • A Current Ratio of 5.47 means the company has €5.47 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 5.467. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.507. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.467TTM5.507-0.040
TTM5.507YOY6.998-1.491
TTM5.5075Y8.212-2.705
5Y8.21210Y8.2120.000
4.4.3.2. Quick Ratio

Measures if Enanta Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Enanta Pharmaceuticals Inc to the  industry mean.
  • A Quick Ratio of 2.86 means the company can pay off €2.86 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 2.855. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.648. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.855TTM3.648-0.793
TTM3.648YOY4.731-1.082
TTM3.6485Y5.666-2.018
5Y5.66610Y5.6660.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Enanta Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Enanta Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Enanta Pharmaceuticals Inc to industry mean.
  • A Debt to Asset Ratio of 0.68 means that Enanta Pharmaceuticals Inc assets are financed with 67.9% credit (debt) and the remaining percentage (100% - 67.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 0.679. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.641. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.679TTM0.641+0.039
TTM0.641YOY0.444+0.196
TTM0.6415Y0.363+0.278
5Y0.36310Y0.3630.000
4.5.4.2. Debt to Equity Ratio

Measures if Enanta Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Enanta Pharmaceuticals Inc to the  industry mean.
  • A Debt to Equity ratio of 211.8% means that company has €2.12 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Enanta Pharmaceuticals Inc:

  • The MRQ is 2.118. The company is just not able to pay all its debts with equity.
  • The TTM is 1.802. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.118TTM1.802+0.316
TTM1.802YOY0.915+0.887
TTM1.8025Y0.837+0.966
5Y0.83710Y0.8370.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Enanta Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Enanta Pharmaceuticals Inc to the  industry mean.
  • A PE ratio of -1.47 means the investor is paying €-1.47 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Enanta Pharmaceuticals Inc:

  • The EOD is -1.558. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.467. Based on the earnings, the company is expensive. -2
  • The TTM is -2.256. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.558MRQ-1.467-0.091
MRQ-1.467TTM-2.256+0.789
TTM-2.256YOY-3.028+0.771
TTM-2.2565Y-5.870+3.614
5Y-5.87010Y-5.8700.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Enanta Pharmaceuticals Inc:

  • The EOD is -1.360. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.280. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.497. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.360MRQ-1.280-0.079
MRQ-1.280TTM-2.497+1.217
TTM-2.497YOY-5.234+2.737
TTM-2.4975Y-8.269+5.772
5Y-8.26910Y-8.2690.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Enanta Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to industry mean).
  • A PB ratio of 1.17 means the investor is paying €1.17 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Enanta Pharmaceuticals Inc:

  • The EOD is 1.243. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.170. Based on the equity, the company is underpriced. +1
  • The TTM is 1.673. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.243MRQ1.170+0.072
MRQ1.170TTM1.673-0.503
TTM1.673YOY1.791-0.118
TTM1.6735Y2.440-0.767
5Y2.44010Y2.4400.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets348,642
Total Liabilities236,826
Total Stockholder Equity111,816
 As reported
Total Liabilities 236,826
Total Stockholder Equity+ 111,816
Total Assets = 348,642

Assets

Total Assets348,642
Total Current Assets268,145
Long-term Assets80,497
Total Current Assets
Cash And Cash Equivalents 84,349
Short-term Investments 132,342
Net Receivables 7,718
Other Current Assets 10,684
Total Current Assets  (as reported)268,145
Total Current Assets  (calculated)235,093
+/- 33,052
Long-term Assets
Property Plant Equipment 77,043
Long-term Assets Other 3,454
Long-term Assets  (as reported)80,497
Long-term Assets  (calculated)80,497
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities49,050
Long-term Liabilities187,776
Total Stockholder Equity111,816
Total Current Liabilities
Accounts payable 4,726
Other Current Liabilities 32,743
Total Current Liabilities  (as reported)49,050
Total Current Liabilities  (calculated)37,469
+/- 11,581
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt57,459
Long-term Liabilities Other 129,973
Long-term Liabilities  (as reported)187,776
Long-term Liabilities  (calculated)187,432
+/- 344
Total Stockholder Equity
Total Stockholder Equity (as reported)111,816
Total Stockholder Equity (calculated)0
+/- 111,816
Other
Capital Stock213
Common Stock Shares Outstanding 21,333
Net Invested Capital 111,816
Net Working Capital 219,095
Property Plant and Equipment Gross 97,172



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-30
> Total Assets 
438,791
440,594
406,818
385,214
375,410
347,534
326,445
495,169
462,275
428,499
413,557
398,821
376,652
348,642
348,642376,652398,821413,557428,499462,275495,169326,445347,534375,410385,214406,818440,594438,791
   > Total Current Assets 
319,021
326,957
341,869
313,035
311,713
283,704
271,137
448,465
422,791
390,303
351,029
286,584
299,852
268,145
268,145299,852286,584351,029390,303422,791448,465271,137283,704311,713313,035341,869326,957319,021
       Cash And Cash Equivalents 
57,206
99,068
40,989
28,367
43,994
42,223
73,178
95,177
85,388
39,933
63,542
35,775
37,233
84,349
84,34937,23335,77563,54239,93385,38895,17773,17842,22343,99428,36740,98999,06857,206
       Short-term Investments 
186,796
159,984
239,338
224,921
205,238
172,247
136,906
291,408
284,522
297,218
236,768
194,310
210,953
132,342
132,342210,953194,310236,768297,218284,522291,408136,906172,247205,238224,921239,338159,984186,796
       Net Receivables 
23,576
27,648
18,716
19,479
20,318
22,585
17,795
18,892
8,614
8,173
7,756
8,176
6,646
7,718
7,7186,6468,1767,7568,1738,61418,89217,79522,58520,31819,47918,71627,64823,576
       Other Current Assets 
0
0
0
0
13,445
17,946
14,484
17,071
13,263
13,245
10,932
15,260
12,413
10,684
10,68412,41315,26010,93213,24513,26317,07114,48417,94613,4450000
   > Long-term Assets 
119,770
113,637
64,949
72,179
63,697
63,830
55,308
46,704
39,484
38,196
62,528
112,237
76,800
80,497
80,49776,800112,23762,52838,19639,48446,70455,30863,83063,69772,17964,949113,637119,770
       Property Plant Equipment 
0
0
0
0
29,748
32,222
35,604
35,982
34,713
33,463
58,373
66,262
73,346
77,043
77,04373,34666,26258,37333,46334,71335,98235,60432,22229,7480000
       Long Term Investments 
108,416
88,668
42,218
39,427
29,285
26,939
15,040
5,924
0
0
0
42,510
0
0
0042,5100005,92415,04026,93929,28539,42742,21888,668108,416
       Long-term Assets Other 
700
700
700
4,671
4,664
4,669
4,664
4,798
4,771
4,733
4,155
3,465
3,454
3,454
3,4543,4543,4654,1554,7334,7714,7984,6644,6694,6644,671700700700
> Total Liabilities 
39,362
56,210
48,235
47,191
54,076
46,697
57,070
257,350
245,540
236,615
247,443
249,906
247,838
236,826
236,826247,838249,906247,443236,615245,540257,35057,07046,69754,07647,19148,23556,21039,362
   > Total Current Liabilities 
36,172
37,890
30,738
23,035
29,827
23,001
32,166
68,189
62,787
62,407
54,608
58,231
57,535
49,050
49,05057,53558,23154,60862,40762,78768,18932,16623,00129,82723,03530,73837,89036,172
       Accounts payable 
9,540
7,841
5,985
1,245
6,000
4,352
11,761
7,932
4,097
9,326
6,726
10,675
8,002
4,726
4,7268,00210,6756,7269,3264,0977,93211,7614,3526,0001,2455,9857,8419,540
       Other Current Liabilities 
0
0
0
0
0
0
0
36,693
35,076
36,512
33,671
32,295
34,462
32,743
32,74334,46232,29533,67136,51235,07636,6930000000
   > Long-term Liabilities 
3,190
18,320
17,497
24,156
24,249
23,696
24,904
189,161
182,753
174,208
192,835
191,675
190,303
187,776
187,776190,303191,675192,835174,208182,753189,16124,90423,69624,24924,15617,49718,3203,190
       Capital Lease Obligations Min Short Term Debt
5,329
19,427
18,128
24,808
25,263
25,345
27,996
27,701
26,513
25,490
46,993
50,567
55,467
57,459
57,45955,46750,56746,99325,49026,51327,70127,99625,34525,26324,80818,12819,4275,329
> Total Stockholder Equity
399,429
384,384
358,583
338,023
321,334
300,837
269,375
237,819
216,735
191,884
166,114
148,915
128,814
111,816
111,816128,814148,915166,114191,884216,735237,819269,375300,837321,334338,023358,583384,384399,429
   Common Stock00000000000000
   Retained Earnings 
48,576
18,461
-15,131
-46,831
-73,179
-102,165
-139,823
-178,888
-206,995
-240,402
-271,559
-294,217
-323,040
-345,330
-345,330-323,040-294,217-271,559-240,402-206,995-178,888-139,823-102,165-73,179-46,831-15,13118,46148,576
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 00000000000000



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-09-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue67,635
Cost of Revenue--
Gross Profit-67,635
 
Operating Income (+$)
Gross Profit-
Operating Expense-189,326
Operating Income-121,691-189,326
 
Operating Expense (+$)
Research Development131,476
Selling General Administrative57,850
Selling And Marketing Expenses-
Operating Expense189,326189,326
 
Net Interest Income (+$)
Interest Income14,770
Interest Expense-10,940
Other Finance Cost-0
Net Interest Income3,830
 
Pretax Income (+$)
Operating Income-121,691
Net Interest Income3,830
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-117,788-121,764
EBIT - interestExpense = -10,940
-116,045
-105,105
Interest Expense10,940
Earnings Before Interest and Taxes (EBIT)--106,848
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-117,788
Tax Provision--1,743
Net Income From Continuing Ops-116,045-116,045
Net Income-116,045
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net73-3,830
 

Technical Analysis of Enanta Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Enanta Pharmaceuticals Inc. The general trend of Enanta Pharmaceuticals Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Enanta Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Enanta Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 8.1 < 8.5 < 8.95.

The bearish price targets are: 5.95 > 5.2 > 4.58.

Tweet this
Enanta Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Enanta Pharmaceuticals Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Enanta Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartEnanta Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Enanta Pharmaceuticals Inc. The current adx is .

Enanta Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartEnanta Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Stochastic Oscillator ChartEnanta Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartEnanta Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartEnanta Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Williams %R ChartEnanta Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Average True Range (ATR) ChartEnanta Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartEnanta Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartEnanta Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Enanta Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-24ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-14STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-20BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-26ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-02ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-24CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-14ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-24STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Enanta Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Enanta Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose6.350
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Enanta Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Enanta Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Enanta Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Enanta Pharmaceuticals Inc

I send you an email if I find something interesting about Enanta Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Enanta Pharmaceuticals Inc.

Receive notifications about Enanta Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.